Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT06721949

PHASE2/PHASE3

Taurine Supplementation in Long COVID

Sponsor: University of Alberta

View on ClinicalTrials.gov

Summary

The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred to as Post-COVID Condition (PCC) or post-acute sequelae of COVID-19, has emerged as a complex multisystemic condition and challenging health issue, affecting approximately 10% of COVID-19 patients. Various symptoms characterize LC, including fatigue, sleep disturbances, cognitive impairment, and mood disturbances. Some of the symptoms are shared with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - a condition marked by debilitating fatigue and a host of other symptoms without precise biomarkers or objective tests for diagnosis. Effective LC treatments remain elusive and LC patients continue to grapple with persistent symptoms that significantly impact their quality of life. Given the lack of effective treatments, it is imperative to explore novel therapeutic approaches that may alleviate the suffering of this patient population.

Official title: Taurine Supplementation as a Novel Therapeutic Approach for Neurocognitive Symptoms in Long COVID

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

300

Start Date

2025-11-18

Completion Date

2028-12

Last Updated

2026-03-16

Healthy Volunteers

Conditions

Long COVID

Interventions

DRUG

Taurine

Taurine is a naturally occurring amino sulfonic acid commonly found in the body. It is marketed as a natural health product/supplement and plays an important role in the body.

DRUG

Placebo

The placebo capsule is visually identical to the taurine capsule.

Inclusion Criteria: 1. Age ≥18 years; 2. Positive COVID-19 test by nasopharyngeal swab RT-PCR test, antibody or antigen tests at least 3 months prior to randomization; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after October 15, 2019, and at least 3 months prior to randomization. 3. If participants have treatable symptoms, they should have had a stable regimen of treatment prior to entering the study (i.e. started treatment for at least 4 weeks). 4. Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive testing or the date of first symptoms. 5. Lingering symptoms from COVID-19 present at the time of randomization. 6. Individuals of childbearing potential (as assessed by the overseeing Investigator) who are sexually active must agree to practice true abstinence or use at least one highly effective method of contraception while on study treatment. Highly effective methods of contraception must be discussed and approved by the overseeing Investigator (refer to Section 5 Contraception of the Master Protocol, and Section 13.1.2 of this protocol). 7. Must be able to provide informed consent and both willing and able to comply with study requirements. 8. Medications prescribed for treating fatigue or cognition have been discontinued for four weeks prior to enrolment and randomization. These include sildenafil, modafinil (Provigil), or armodafinil (Nuvigil), guanfacine, N-acetyl cysteine, and stimulant medications used for attention-deficit hyperactivity disorder (ADHD). Exclusion Criteria: 1. Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19. 2. Current end-organ failure, organ transplantation, or current hospitalization in an acute care hospital. 3. Contraindications to the study intervention. 4. Currently already on study intervention(s). 5. Co-enrolment in another interventional trial (co-enrolment in an observational study is permitted). 6. Currently pregnant or breastfeeding. 7. The participant is currently enrolled in another clinical trial to treat neurocognitive symptoms in LC.

Locations (5)

University of Alberta Hospital, Kaye Edmonton Clinic

Edmonton, Alberta, Canada

BC Women's Hospital

Vancouver, British Columbia, Canada

University Health Network

Toronto, Ontario, Canada

Institut de recherches cliniques de Montréal

Montreal, Quebec, Canada

Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke

Sherbrooke, Quebec, Canada